TrenaTrex®150 10ml vial
Trenbolone Acetate 150mg/ml, 10 mL Multidose Vial
Therapeutic Class:
Anabolic Agent
Composition:
Each 1 ml of TRENATREX150 contains
150 mg Trenbolone Acetate
Ethlyl Oleate q.s.
For Intramuscular Administration
Indication & Dosage:
FOR INTRAMUSCULAR USE FOR FEEDLOT CATTLE
Certain pathophysiological or catabolic processes in animals.
As anabolic after debilitating illness
The dosage for cattle is 0.55 to 2.1 mg/ of animal body
weight intramuscularly. Treatment may be repeated every 2 to 3 weeks.
The condition should be assessed by a veterinarian to determine the
duration of treatment; however, most horses will respond with one or two treatments.
Contraindications:
In the absence of data on the effect of trenbolone acetate on immature colts and
fillies, stallions, pregnant mares or brood mares during the breeding season, this drug should not be used in these animals.
Special Precautions
For feedlot catlle only. This drug is not to be administered to horses that are to be slaughtered
for use in food. Keep out of reach of children.
Adverse Drug Reactions
Treatment with TRENATREX injectable (trenbolone acetate injection) may
result in androgenic effects (masculinization, behavioural effects) being expressed
in some animals. If these effects occur, they may persist for up to 6 to 8 weeks.
No additional injections of boldenone undecylenate should be administered.
Drug Interactions
May increase effects of oral anticoagulants, insulin, oral antidiabetic agents, adrenal steroid, adrenocorticotropic hormone (ACTH).
Pregnancy Category
Category X: Studies in animals beings have demonstrated foetal abnormalities or there is evidence of foetal risk.
Storage:
Store at room temperature, between 59 and 86 degrees F (15 and 30 degrees C), in a tightly-closed container. Store away from heat, moisture, and light.
Do not store in the bathroom. Keep out of the reach of children and away from pets.
Concentrex Laboratiories N. V., Moerstraat 58, 9031, Gent, Belgium
Reg. No. Licence: 253/55-C9/2010/BE
Manufactured under WHO cGMP guidelines
www.concentrexlabs.com
Date of Preparation : 19 july 2010